UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 144

Sortiert nach

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Clinical cancer research, 2019-01, Vol.25 (1), p.90-98

2019

Volltextzugriff (PDF)

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

Cancer chemotherapy and pharmacology, 2023-07, Vol.92 (1), p.15-28

2023

Volltextzugriff (PDF)

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

Cancers, 2022-10, Vol.14 (20), p.4996

2022

Volltextzugriff (PDF)

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-09, Vol.23 (18), p.5349-5357

2017

Volltextzugriff (PDF)

Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy

Journal of thoracic oncology, 2011-02, Vol.6 (2), p.365-371

2011

Volltextzugriff (PDF)

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Clinical cancer research, 2012-04, Vol.18 (8), p.2316-2325

2012

Volltextzugriff (PDF)

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Clinical cancer research, 2019-09, Vol.25 (18), p.5458-5465

2019

Volltextzugriff (PDF)

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Cancer chemotherapy and pharmacology, 2015-01, Vol.75 (1), p.183-189

2015

Volltextzugriff (PDF)

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Clinical cancer research, 2016-03, Vol.22 (5), p.1095-1102

2016

Volltextzugriff (PDF)

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Clinical cancer research, 2014-10, Vol.20 (19), p.5032-5040

2014

Volltextzugriff (PDF)

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Cancer chemotherapy and pharmacology, 2022-01, Vol.89 (1), p.93-103

2022

Volltextzugriff (PDF)

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Clinical cancer research, 2018-09, Vol.24 (17), p.4072-4080

2018

Volltextzugriff (PDF)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

Journal of clinical pharmacology, 2018-02, Vol.58 (2), p.180-192

2018

Volltextzugriff (PDF)

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-02, Vol.73 (2), p.363-371

2014

Volltextzugriff (PDF)

The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research

The oncologist (Dayton, Ohio), 2009-05, Vol.14 (5), p.468-475

2009

Volltextzugriff (PDF)

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

Investigational new drugs, 2022-08, Vol.40 (4), p.762-772

2022

Volltextzugriff (PDF)

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

Targeted oncology, 2022-03, Vol.17 (2), p.125-138

2022

Volltextzugriff (PDF)

Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population

Journal of thoracic oncology, 2010-10, Vol.5 (10), p.1529-1535

2010

Volltextzugriff (PDF)

Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

Targeted oncology, 2022-03, Vol.17 (2), p.139-139

2022

Volltextzugriff (PDF)

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer

Patient education and counseling, 2012-10, Vol.89 (1), p.102-108

2012

Volltextzugriff (PDF)

Integrating Metastasectomy in the Management of Advanced Urological Malignancies—Where are we in 2005?

The Journal of urology, 2006-11, Vol.176 (5), p.1921-1926

2006

Volltextzugriff (PDF)

A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.115-115

2023

Volltextzugriff (PDF)

Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.445-445

2017

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(144)

Sprache

Englisch
(144)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(25)
Oncology
(25)
Male
(21)
Female
(19)
Middle Aged
(19)
Aged
(18)
Adult
(16)
Neoplasms - Drug Therapy
(13)
Treatment Outcome
(13)
Maximum Tolerated Dose
(11)
Tumors
(11)
Aged, 80 And Over
(8)
Medicine
(8)
Medicine & Public Health
(8)
Neoplasms - Pathology
(8)
Antineoplastic Agents - Therapeutic Use
(7)
Cancer Research
(7)
Pharmacology & Pharmacy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(75)
Cancer Research
(16)
Molecular Cancer Therapeutics
(15)
Blood
(9)
Clinical Cancer Research
(9)
Cancer Chemotherapy And Pharmacology
(5)
Journal Of Thoracic Oncology
(2)
Targeted Oncology
(2)
Cancer
(1)
Cancer Discovery
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

A Phase I Dose-Escalation and Dose-Expansion Study of FCN-437c, a Novel CDK4/6 Inhibitor, in Patients with Advanced Solid Tumors

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

The Impact of Consenter Characteristics and Experience on Patient Interest in Clinical Research

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study

Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population

Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer

Integrating Metastasectomy in the Management of Advanced Urological Malignancies—Where are we in 2005?

A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers

Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b

Suchergebnisse filtern